Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
The Ras Gene02:38

The Ras Gene

7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

17.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
17.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methotrexate inhibits the TEL-JAK2-STAT pathway through a folate metabolism-dependent mechanism in Ba/F3 cells.

International immunopharmacology·2026
Same author

A critical role for STAT3 Thr714 phosphorylation in NPM-ALK-driven tumorigenesis.

Scientific reports·2026
Same author

DDX5: a versatile RNA helicase in cancer and cell fate determination-linking c-Myc and JAK2 V617F signalling to emerging therapeutics.

Journal of biochemistry·2026
Same author

Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms.

International immunopharmacology·2026
Same author

KMN003 activates Nrf2 via disruption of the Keap1-Nrf2 interaction and p38-dependent transcriptional regulation.

Cellular signalling·2026
Same author

DDX5 is required for JAK2V617F-induced cell proliferation and tumorigenesis independent of its RNA helicase activity.

Cellular signalling·2025

Related Experiment Video

Updated: Jan 11, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

STK38 Kinase Promotes Cell Migration Induced by Oncogenic Ras via MerTK Activation.

Satoshi Ohta1, Kenji Tago2, Katsumi Kasashima1

  • 1Division of Structural Biochemistry, Department of Biochemistry, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan.

International Journal of Molecular Sciences
|November 13, 2025
PubMed
Summary

Oncogenic Ras promotes cancer cell migration by upregulating the receptor tyrosine kinase MerTK. This study identifies STK38 as a key kinase in this pathway, offering new therapeutic targets for Ras-mutated cancers.

Keywords:
MerTKRasSTK38cell migration

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

611

Related Experiment Videos

Last Updated: Jan 11, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

611

Area of Science:

  • Molecular oncology
  • Cell signaling pathways

Background:

  • Ras gene mutations are common in various cancers, yet effective treatments remain limited.
  • Oncogenic Ras signaling drives cancer progression through downstream effectors, necessitating identification of novel therapeutic targets.

Purpose of the Study:

  • To identify novel downstream effectors of oncogenic Ras signaling involved in cancer cell migration.
  • To elucidate the role of the serine/threonine kinase STK38 in Ras-induced cell migration.

Main Methods:

  • Purification of the MerTK complex from Ras-transformed NIH-3T3 cells.
  • Mass spectrometric analysis to identify binding partners of MerTK.
  • Knockdown studies of MerTK and STK38 to assess their impact on cell migration and signaling pathways.
  • Assessment of kinase activity and downstream effector activation (Rac1, Cdc42).

Main Results:

  • STK38 was identified as a MerTK binding partner in Ras-transformed cells.
  • Knockdown of STK38 or MerTK significantly attenuated H-Ras (G12V)-induced NIH-3T3 cell migration.
  • STK38 kinase activity was essential for Ras-induced cell migration and MerTK phosphorylation.
  • STK38 and MerTK are involved in the activation of Rac1 and Cdc42.

Conclusions:

  • STK38 plays a critical role in oncogenic Ras-induced cell migration, acting downstream of Ras and interacting with MerTK.
  • The MerTK-STK38 axis represents a potential therapeutic target for cancers with Ras mutations.